Check Out What Whales Are Doing With MRNA
Portfolio Pulse from Benzinga Insights
Deep-pocketed investors have shown a significant interest in Moderna (NASDAQ:MRNA), with a split sentiment of 50% bullish and 41% bearish among them. Benzinga's tracking of public options records revealed 12 extraordinary options activities, indicating a targeted price range for Moderna between $90.0 and $180.0 over the last 3 months. The trading volume of MRNA is up by 0.56%, with a current price of $122.82, and its next earnings report is scheduled in 86 days. Moderna's mRNA technology has been rapidly validated with its COVID-19 vaccine, and it has 39 mRNA development candidates in clinical trials.
May 07, 2024 | 5:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna has attracted significant attention from large investors, with a balanced mix of bullish and bearish sentiments. The company's stock price has recently increased, and it is involved in numerous mRNA development projects.
The significant interest from deep-pocketed investors, especially in options trading, suggests a positive outlook on Moderna's stock in the short term. The bullish sentiment, despite being balanced with some bearish views, along with the current uptick in stock price and the anticipation of the next earnings report, could lead to increased investor confidence and potentially drive the stock price up.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100